Drug Profile
ISIS FVIIRx
Alternative Names: ISIS-FVIIRxLatest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Factor VII modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 01 Mar 2023 Discontinued - Preclinical for Thrombosis (Prevention) in USA (Parenteral)
- 01 Mar 2023 Discontinued - Preclinical for Thrombosis in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Thrombosis in USA (Parenteral)